Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
IQVIA Holdings Inc (IQV)
NYSE:IQV
Holding IQV?
Track your performance easily
Earnings Data
Report Date
Feb 12, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$3.11Last Year’s EPS
$2.84Same Quarter Last Year
Strong Buy
Based on 22 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 31, 2024
|% Change Since: -8.69%
|Next Earnings Date:Feb 12, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue and EPS growth, a record backlog, and successful strategic partnerships, indicating robust operational performance. However, the company faces challenges in the clinical market environment, significant trial cancellations, and delays in mega trials, which have impacted short-term guidance. Pricing pressures are also a concern across segments.Company Guidance
During the IQVIA Q3 2024 earnings call, the company provided several key metrics and updates on their performance and guidance. Revenue for the quarter reached $3.896 billion, growing 4.3% on a reported basis and 4.2% at constant currency. Excluding COVID-related revenues, the company achieved a 6.5% growth, with organic growth just under 5%. The Technology & Analytics Solutions segment showed strong performance with an 8.6% increase in revenue. Meanwhile, R&D Solutions revenue grew by 1.9% reported and 2% at constant currency, excluding COVID-related work. The company's backlog hit a record $31.1 billion, representing an 8% year-over-year growth. Despite facing challenges such as a $350 million cancellation due to drug futility and delays in two mega trials, IQVIA remains optimistic about its future growth, expecting TAS to grow approximately 6% and R&D to grow around 5% for the full year. The company also reported a 14% increase in adjusted diluted EPS to $2.84. Looking ahead, the company plans to address logistical delays in trials and anticipates a strong demand environment into 2025.Revenue Exceeds Expectations
IQVIA's revenue for Q3 2024 came in above the high end of the guidance range, representing about 6.5% growth excluding the impact of foreign exchange and COVID-related work.
Strong EPS Growth
Adjusted diluted EPS grew by 14% year-over-year.
Record Backlog
IQVIA's backlog reached a new record of $31.1 billion, representing an 8% year-over-year growth.
Successful Strategic Partnerships
IQVIA successfully renewed every large pharma strategic partnership and expanded scope in over half a dozen partnerships.
Strong Cash Flow
Free cash flow was $571 million, representing a 31% year-over-year increase and 109% cash conversion of adjusted net income.
---
IQV Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
IQV Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 31, 2024 | $216.04 | $205.82 | -4.73% |
| Jul 22, 2024 | $224.57 | $245.23 | +9.20% |
| May 02, 2024 | $232.94 | $222.14 | -4.64% |
| Feb 14, 2024 | $215.27 | $243.47 | +13.10% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does IQVIA Holdings Inc (IQV) report earnings?
IQVIA Holdings Inc (IQV) is schdueled to report earning on Feb 12, 2025, TBA Not Confirmed.
What is IQVIA Holdings Inc (IQV) earnings time?
IQVIA Holdings Inc (IQV) earnings time is at Feb 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IQV EPS forecast?
IQV EPS forecast for the fiscal quarter 2024 (Q4) is $3.11.
---